The Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad.p53-DC) is an investigational immune stimulating therapy designed to activate the immune system to attack tumor cells that express high levels of p53 which occurs in many types of cancer.

The Ad.p53-DC vaccine is comprised of the cancer patient’s dendritic cells, a type of immune cell, infected in the laboratory with a genetically engineered adenovirus carrying the human p53 gene (Ad-p53).

The Ad.p53-DC vaccine is then injected into the patient’s skin. The Ad.p53-DC vaccination treatment is combined with Nivolumab and Ipilimumab immune therapies. Nivolumab and Ipilimumab have been approved for the treatment of other forms of cancer.